Correction to: Prostate Cancer and Prostatic Diseases https://doi.org/10.1038/s41391-021-00318-3, published online 21 February 2021
In the sentence beginning ‘After adjusting for age...’ in this article, the value of upper CI limit ‘0.84’ should have read ‘0.94’.
In the sentence beginning ‘Unlike the overall population...’ in this article, the value ‘n = 700’ should have read ‘n = 786’.
In the sentence beginning ‘Nearly half (46,5%)...’ in this article, the value ‘46,5%’ should have read ‘49,5%’.
In Table 2 in the Supplementary PDF for this article, the line ‘Abiraterone followed by chemotherapy (c) 74 (3.80)’ has been deleted.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Tagawa, S.T., Ramaswamy, K., Huang, A. et al. Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis 25, 804 (2022). https://doi.org/10.1038/s41391-022-00578-7
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41391-022-00578-7
